Navigation Links
Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
Date:5/26/2009

ROCKVILLE, Md., May 26 /PRNewswire/ -- Theranostics Health, Inc. (TH) is pleased to announce its involvement in a five-year clinical research study funded by the Susan G. Komen Foundation. TH's collaborator, Duke University, was the recipient of a Promise Grant, part of over $25 million of investment by the foundation in 2009 to further the development of new prevention and treatment options for breast cancer.

The Susan G. Komen for the Cure(R) is a nonprofit organization dedicated to improving the lives of breast cancer patients through funding groundbreaking research. Since its inception nearly 30 years ago, the foundation has invested over $400 million. This year alone, grants will go to 54 universities and hospitals in 26 states and one foreign country, all for addressing the challenges associated with breast cancer.

Theranostics Health has been collaborating with researchers at Duke University as part of the collaboration agreement established in May 2008. Studies conducted by Theranostics Health with Dr. Victoria Seewaldt, MD, a Duke investigator, have provided the underlying rationale and preliminary data in support of the research proposed for the Promise Grant. Dr. Seewaldt is dedicated to discovering and developing new prevention and treatment strategies for each of her patients afflicted with breast cancer.

Theranostics Health will use its pathway mapping platform to measure signaling pathway activation in hundreds of key signaling proteins directly from randomly obtained periareolar breast fine-needle aspiration to assess individual response to chemoprevention in high-risk patients. This information can be used to develop a rapid test that matches the right prevention agent to each patient based on the biology of abnormal cells in each woman's body.

"The power of this new technology is that it gives us the possibility of tracking how a woman is or is not responding to a prevention drug," said Dr. Victoria Seewaldt. "If this project is successful, it will pave the way for quickly testing the effectiveness of prevention drugs as well as biological response to exercise."

"We are very pleased to have the opportunity of working with first-class research clinicians like Dr. Seewaldt. We share the same vision as Dr. Seewaldt in that each patient's tumor is different and an individualized assessment and approach is needed to effectively prevent and treat diseases," noted Dr. Danong Chen, President and CEO of Theranostics Health.

About Theranostics Health

Theranostics Health (TH) is a privately held company founded in 2006. Its proprietary technology platform includes fixative reagents, Laser Capture Microdissection (LCM), and Reverse Phase Protein Microarray (RPMA). TH's proprietary fixatives are developed to both preserve cell morphology and fix the state of cellular activities for molecular analysis. LCM is used to isolate specific cell populations from many different types of cells usually present in a clinical biopsy. Therefore, information derived from subsequent molecular assays is specific to that cell population. RPMA enables sensitive, quantitative, calibrated, multiplexed analysis of cellular proteins from a limited amount of starting materials, such as clinical specimens. TH has an exclusive license from the National Institute of Health (NIH) to commercialize microdissection, including LCM, combined with protein analysis for cancer diagnostics and companion diagnostics. While providing research and development services to pharmaceutical companies and academic institutions for efficient and effective target discovery and drug development, TH is developing clinical tests, enabling physicians to tailor optimized therapies for patients based on the biomarker profile of each patient's disease specimen. The technology, developed by the company's scientific co-founders, Drs. Emanuel Petricoin and Lance Liotta, was first published in 2001 and in the past 2 years has been used in studies published in more than 50 peer-reviewed journals and presentations. TH's technology was also successfully used in NCI-sponsored clinical trials. For more information please email info@theranosticshealth.com or visit http://www.theranosticshealth.com/.


'/>"/>
SOURCE Theranostics Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
2. Theranostics Health Receives Green Light to Perform Clinical Testing
3. American Lung Association Offers Simple Tips to Protect Public Health and Minimize H1N1 Flu (Swine Flu) and Seasonal Flu Transmission
4. New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health
5. Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels
6. MedNet Solutions Certified to Score SF-12v2 Health Survey
7. Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase
8. First Human Study to Show Sun Chlorella A Supports Heart Health
9. Nations Laboratory Response Network Marks First Decade of Protecting Public Health
10. Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):